Ladenburg Thalmann Financial Services’s Akebia Therapeutics AKBA Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$5K	Sell	788 -951	-55%	-$4.52K	﹤0.01%	4753
2019 Q3	$7K	Sell	1,739 -304	-15%	-$1.3K	﹤0.01%	4524
2019 Q2	$10K	Buy	2,043 +797	+64%	+$4.53K	﹤0.01%	4421
2019 Q1	$10K	Sell	1,246 -61	-5%	-$419	﹤0.01%	4353
2018 Q4	$7K	Buy	+1,307	New	+$10.2K	﹤0.01%	4437
2018 Q3	–	Sell	-59	Closed	-$1K	–	5134
2018 Q2	$1K	Hold	59	–	–	﹤0.01%	4949
2018 Q1	$1K	Hold	59	–	–	﹤0.01%	4949
2017 Q4	$1K	Hold	59	–	–	﹤0.01%	4869
2017 Q3	$1K	Hold	59	–	–	﹤0.01%	4759
2017 Q2	$1K	Hold	59	–	–	﹤0.01%	4696
2017 Q1	$1K	Hold	59	–	–	﹤0.01%	4671
2016 Q4	$1K	Hold	59	–	–	﹤0.01%	4618
2016 Q3	$1K	Hold	59	–	–	﹤0.01%	4583
2016 Q2	$0	Hold	59	–	–	﹤0.01%	4730
2016 Q1	$1K	Sell	59 -67	-53%	-$543	﹤0.01%	4478
2015 Q4	$2K	Buy	+126	New	+$1.29K	﹤0.01%	4325

Other funds holding AKBA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ladenburg Thalmann Financial Services's AKBA Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its Akebia Therapeutics (AKBA) stake by 55% in Q4 2019, selling an estimated $4.52K and leaving 788 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #4753.

Ladenburg Thalmann Financial Services first reported a position in AKBA in Q4 2015 and has held it in 16 quarters since. The position peaked at $10K in Q2 2019. 153 funds tracked by Wall St. Rank hold AKBA as of Q4 2019.

Ladenburg Thalmann Financial Services held 788 shares of Akebia Therapeutics worth $5K as of Q4 2019.
Ladenburg Thalmann Financial Services sold 951 Akebia Therapeutics shares in Q4 2019, an estimated $4.52K.
Akebia Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4753 holding.
Ladenburg Thalmann Financial Services first reported a position in Akebia Therapeutics in Q4 2015 and has held it in 16 quarters since.
Ladenburg Thalmann Financial Services's Akebia Therapeutics position peaked at $10K in Q2 2019.
153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.